Patents Examined by Michael J Schmitt
  • Patent number: 11497724
    Abstract: Compounds, pharmaceutically acceptable salts, esters, prodrugs, and pharmaceutical compositions thereof are disclosed that are useful for inhibition of the biological activity of CCL5 on mammalian cells, as well as methods of treatment for diseases involving the increased biological activity of CCL5.
    Type: Grant
    Filed: January 20, 2022
    Date of Patent: November 15, 2022
    Assignee: LAPKO INC
    Inventor: Bruce Kovacs
  • Patent number: 11491130
    Abstract: Disclosed are methods for inhibiting the progression of neurodegenerative disease. The methods include administering to a patient suffering from such a disease a composition comprising either deuterated linoleic acid or an ester thereof.
    Type: Grant
    Filed: August 2, 2021
    Date of Patent: November 8, 2022
    Assignee: Retrotope, Inc.
    Inventors: Peter Milner, Mikhail Sergeevich Shchepinov
  • Patent number: 11492353
    Abstract: Provided are methods for treating Paramyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula I: wherein the 1? position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Human parainfluenza and Human respiratory syncytial virus infections.
    Type: Grant
    Filed: May 20, 2020
    Date of Patent: November 8, 2022
    Assignee: Gilead Sciences, Inc.
    Inventors: Richard L. Mackman, Jay P. Parrish, Adrian S. Ray, Dorothy Agnes Theodore
  • Patent number: 11485705
    Abstract: Presently provided are indoximod prodrug and salt compounds and pharmaceutical compositions comprising salts and prodrugs of indoximod, that produce enhanced plasma concentration and exposure to indoximod compared to direct administration of indoximod, in patients in need of treatment of immunosuppression mediated by the indoleamine-2,3-dioxygenase pathway, such as patients with cancer or chronic infectious diseases.
    Type: Grant
    Filed: May 22, 2020
    Date of Patent: November 1, 2022
    Assignee: LUMOS PHARMA, INC.
    Inventors: Mario Mautino, Sanjeev Kumar, Firoz Jaipuri, Jesse Waldo, Hima Potturi, Hong Zhuang
  • Patent number: 11485755
    Abstract: This invention provides a method of synthesizing new active compounds for pharmaceutical uses including cancer treatment, wherein the cancers comprise breast, leukocytic, liver, ovarian, bladder, prostatic, skin, bone, brain, leukemia, lung, colon, CNS, melanoma, renal, cervical, esophageal, testicular, spleenic, kidney, lymphatic, pancreatic, stomach and thyroid cancers. This invention is an anti-adhesion therapy which uses the compound as a mediator or inhibitor of adhesion proteins and angiopoietins. It inhibits excess adhesion and inhibits cell attachment. It modulates angiogenesis. The compounds also use as mediator of cell adhesion receptor, cell circulating, cell moving and inflammatory diseases.
    Type: Grant
    Filed: February 17, 2020
    Date of Patent: November 1, 2022
    Inventors: Pui-Kwong Chan, May Sung Mak
  • Patent number: 11478441
    Abstract: The invention provides a method, composition and kit for treating T-cell mediated diseases, degenerative joint diseases or diseases mediated by platelet activating factor (PAF) comprising administering to an animal in need thereof, an effective amount a pharmaceutical composition containing N-acetyl-kynurenine (NAK) or pharmaceutically acceptable salts thereof as the active ingredient.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: October 25, 2022
    Assignee: Ampio Pharmaceuticals, Inc.
    Inventors: David Bar-Or, Leonard T. Rael, Raphael Bar-Or
  • Patent number: 11467160
    Abstract: The present invention relates to method of therapy selection for patient suffering from glioblastoma. Using in vitro and in vivo approaches, the inventors demonstrated the critical role of CD90 in GBM migration/invasion. They showed that CD90 signaling though SRC, FAK and RhoA promotes cell migration and importantly, that high CD90 expression impacts on the cell response to the SRC inhibitor dasatinib. In particular, the present invention relates to a method for predicting whether a subject will be eligible to a treatment with a drug selected from the group consisting of SRC inhibitor, FAK inhibitor or RhoA inhibitor by determining the expression level of CD90 in a sample obtained from the subject.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: October 11, 2022
    Assignees: INSERM (INSTITUT NAITONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE RENNES I, CENTRE EUGENE MARQUIS, ENIOS APPLICATIONS PRIVATE LIMITED COMPANY
    Inventors: Eric Chevet, Tony Avril, Aristotelis Chatziioannou
  • Patent number: 11465979
    Abstract: A method for manufacturing an insecticidal compound and insecticidal compositions comprising the insecticidal compound and methods of use are presented herein. The manufacturing method presented herein allows for a high purity grade of thiocyclam hydrochloride to be synthesized. The insecticidal compositions comprising the thiocyclam hydrochloride can be used for prevention of crop destruction by insects. The use of thiocyclam hydrochloride in insecticidal compositions as described herein can achieve greater efficacy than previously known insecticides, by eliminating the insect pests more reliably and efficiently.
    Type: Grant
    Filed: March 4, 2020
    Date of Patent: October 11, 2022
    Assignee: ARYSTA LIFESCIENCE NORTH AMERICA, LLC
    Inventors: Cameron S. Gibb, Christopher L. Larson, Mark T. Singleton, Kamal L. Kataria, Samantha Besse, Joseph A. Moore, III, Thomas C. Lovelace, Chandra S. Kanugala, Srinivas Vollala, Balraju Vadla
  • Patent number: 11458150
    Abstract: A composition that includes methylphosphinic acid or a salt thereof, and optionally methylphosphonic acid or a salt thereof, and an ingredient acceptable for consumption by a mammal is provided herein. Also provided is a method for reducing aging in a mammal that involves providing or administering methylphosphinic acid or a salt thereof, and optionally, methylphosphonic acid or a salt thereof, to the mammal in need thereof for consumption. A composition for use in such a method and an article useful for such a method include those in the form of a food product such as a prepackaged or processed food or meal, a beverage, a nutritional supplement, or a nutraceutical.
    Type: Grant
    Filed: July 22, 2020
    Date of Patent: October 4, 2022
    Inventor: Gerald E. Aardsma
  • Patent number: 11458158
    Abstract: Described herein are compounds and compositions characterized, in certain embodiments, by conjugation of various groups, such as lipophilic groups, to an amino or amide group of an amino acid, a linear or cyclic peptide, a linear or cyclic polypeptide, or structural isomer thereof, to provide compounds of the present invention, collectively referred to herein as “APPLs”. Such APPLs are deemed useful for a variety of applications, such as, for example, improved nucleotide delivery. Exemplary APPLs include, but are not limited to, compounds of Formula (I), (II), (III), (IV), (V), and (VI), and salts thereof, as described herein: wherein m, n, p, R?, R1, R2, R3, R4, R5, R8, Z, W, Y, and Z are as defined herein.
    Type: Grant
    Filed: May 5, 2020
    Date of Patent: October 4, 2022
    Assignee: Massachusetts Institute of Technology
    Inventors: Yizhou Dong, Kevin Thomas Love, Robert S. Langer, Daniel Griffith Anderson, Delai Chen, Yi Chen, Arturo Jose Vegas, Akinleye C. Alabi, Yunlong Zhang
  • Patent number: 11458127
    Abstract: Provided are methods of treating a brain tumor in a patient in need thereof comprising administering to the patient a compound described herein and radiation therapy and/or one or more additional therapeutic agents.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: October 4, 2022
    Assignee: AGIOS PHARMACEUTICALS, INC.
    Inventors: Joshua Murtie, Nelamangala Nagaraja, Brandon Nicolay, David Schenkein, Katharine Yen
  • Patent number: 11420972
    Abstract: Provided are methods for treating Paramyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula I: wherein the 1? position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Human parainfluenza and Human respiratory syncytial virus infections.
    Type: Grant
    Filed: May 20, 2020
    Date of Patent: August 23, 2022
    Assignee: Gilead Sciences, Inc.
    Inventors: Richard L. Mackman, Jay P. Parrish, Adrian S. Ray, Dorothy Agnes Theodore
  • Patent number: 11382872
    Abstract: The present invention relates to LSD1 inhibitors and their uses as skeletal muscle hypertrophy inducers as well as to promote skeletal muscle regeneration, to prevent skeletal muscle atrophy, or in the treatment or prevention of a disease or injury resulting in loss of skeletal muscle tissue and/or muscle weakness. It further relates to the non-therapeutic use of such compounds to increase muscle mass, muscle strength and/or muscle performance in a subject.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: July 12, 2022
    Assignee: CYTOO
    Inventors: Pauline Poydenot, Joris Michaud, Mélanie Flaender, Eve Duchemin-Pelletier, Luc Selig
  • Patent number: 11382894
    Abstract: The inventors demonstrate that the phosphatase and hydrolase domains of soluble epoxide hydrolase (sEH) regulate the cardiovascular calcification process and revealed that inhibition of the phosphatase domain of sEH could represent a new pharmacological target in the prevention of cardiovascular calcification. The present invention thus relates to a therapeutically effective amount of an inhibitor of phosphatase activity of soluble epoxide hydrolase for use in a method of treating cardiovascular calcification in a subject in need thereof.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: July 12, 2022
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE ROUEN NORMANDIE, UNIVERSITE DE PICARDIE JULES VERNE, CENTRE HOSPITALIER UNIVERSITAIRE DE ROUEN, CENTRE HOSPITALIER UNIVERSITAIRE D'AMIENS
    Inventors: Jeremy Bellien, Isabelle Six, Romuald Mentaverri, Said Kamel
  • Patent number: 11382879
    Abstract: Methods of improving physical performance and endurance include administering a capsicum composition to a subject. More particularly the methods include administration of an effective amount of a capsicum composition including capsaicinoids alone and/or in combination with other nutrients for improvement in performance of physical activities. The methods described include administration of a capsicum composition to a subject undergoing physical activity to deliver daily dose of capsaicinoids in an effective amount. The methods include administering a capsicum composition to a subject in an effective amount to reduce blood lipids and oxidative stress. Methods for enhancing physical endurance and exhaustion time include administering an effective amount of a capsicum composition to a physically active subject, wherein body antioxidants are increased and muscle lactates are decreased, resulting in recovery from muscle fatigue arising due to such indoor and/or outdoor physical activities.
    Type: Grant
    Filed: August 29, 2017
    Date of Patent: July 12, 2022
    Assignee: OmniActive Health Technologies Limited
    Inventors: Jayant Deshpande, Khadija Ghanam, Vijaya Juturu
  • Patent number: 11382904
    Abstract: The present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress. Specifically, the present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress in the corneal epithelium, the drug containing a TGF?-signal inhibitor. As a preferred TGF?-signal inhibitor, the drug contains 4-[4-(1,3-benzodioxole-5-yl)-5-(2-pyridinyl)-1H-imidazole-2-yl]benzamide.
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: July 12, 2022
    Assignees: Kyoto Prefectural Public University Corporation, The Doshisha, Senju Pharmaceutical Co., Ltd.
    Inventors: Noriko Koizumi, Naoki Okumura, Shigeru Kinoshita
  • Patent number: 11369577
    Abstract: The present invention relates to iPSC produced from fibroblast obtained from a subject affected by a neurodevelopmental disorder entailing intellectual disability (ID) and/or a disorder belonging to the Autism Spectrum Disorder (ASD) and/or Schizophrenia (SZ) and uses thereof. The present invention also relates to a cortical neural progenitor cell or a terminally differentiated cortical glutamatergic or gabaergic neuronal cell or a neural crest stem cell line, a mesenchymal stem cell line produced from the iPSC or iPSC line. The invention also relates to method for identifying a compound for the treatment and/or prevention of a neurodevelopmental disorder entailing intellectual disability (ID) and/or a disorder belonging to the Autism Spectrum Disorder (ASD) and/or Schizophrenia (SZ) and to a LSD1 inhibitor or a HDAC2 inhibitor for use in the treatment of such disorders.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: June 28, 2022
    Assignees: IEO—Istituto Europeo di Oncologia S.r.l., I.R.C.C.S. “Casa Sollievo della Sofferenza”, Università degli Studi di Milano
    Inventors: Giuseppe Testa, Sina Atashpazgargari, Antonio Adamo, Pierre-Luc Germain, Giuseppe Merla, Giuseppe D'Agostino, Matteo Zanella
  • Patent number: 11366100
    Abstract: The present invention is based, in part, on the identification of novel FI.3K-mTORCI-S6K 1 signaling pathway biomarkers predictive of responsiveness to anti-cancer therapies.
    Type: Grant
    Filed: February 12, 2015
    Date of Patent: June 21, 2022
    Assignees: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: Thomas M. Roberts, Haoxuan Tong, Jean Zhao, John Blenis
  • Patent number: 11357782
    Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.
    Type: Grant
    Filed: September 27, 2021
    Date of Patent: June 14, 2022
    Assignee: United Therapeutics Corporation
    Inventors: Horst Olschewski, Robert Roscigno, Lewis J. Rubin, Thomas Schmehl, Werner Seeger, Carl Sterritt, Robert Voswinckel
  • Patent number: 11351143
    Abstract: Disclosed are methods for inhibiting the progression of Amyotrophic Lateral Sclerosis (ALS). The methods include administering to a patient suffering from ALS a composition comprising either deuterated linoleic acid or an ester or deuterated arachidonic acid or an ester thereof.
    Type: Grant
    Filed: February 5, 2021
    Date of Patent: June 7, 2022
    Assignee: RETROTOPE, INC.
    Inventors: Peter Milner, Mikhail Sergeevich Shchepinov